An ongoing phase I/II clinical trial is investigating transfer of T-cells engineered to express a G12D specific murine T-cell receptor (TCR) in HLA-A*11:01 patients with solid tumors, including pancreatic cancer, harboring the KRAS G12D mutation (NCT03745326). The gene discussed is KRAS; the disease is pancreatic neoplasm.